Form 8-K - Current report:
SEC Accession No. 0001193125-25-148897
Filing Date
2025-06-26
Accepted
2025-06-26 16:07:08
Documents
12
Period of Report
2025-06-20
Items
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K d917552d8k.htm   iXBRL 8-K 24608
  Complete submission text file 0001193125-25-148897.txt   134564

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lyel-20250620.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20250620_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20250620_pre.xml EX-101.PRE 10809
14 EXTRACTED XBRL INSTANCE DOCUMENT d917552d8k_htm.xml XML 3508
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 251080418
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)